IMUGENE LIMITED — Board/Management Information 2017

Dec 3, 2017

==> picture [167 x 75] intentionally omitted <==

ASX Announcement

International Cancer Specialist Joins Imugene’s Scientific Advisory Board

MELBOURNE, Australia 4 December 2017: Imugene Limited (ASX: IMU), a clinicalstage immuno-oncology company today announced the appointment of London-based cancer specialist Professor Peter Schmid to its Scientific Advisory Board.

Prof Schmid is Chair of Cancer Medicine at the prestigious Barts Cancer Institute at Queen Mary University London. He is also Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. He leads the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre.

Prof Schmid’s specialist cancer interests are breast and lung cancer, cancer immune therapy and early drug development.

He has successfully led more than 20 national and international academic clinical studies and is a member of several national and international cancer organizations and research groups. He has authored or co-authored 165 publications and published a book on the management of bone metastases currently in its third edition.

Imugene’s Scientific Advisory Board works closely with management to maximise the potential of its therapy pipeline and rapidly progress its assets through pre-clinical and clinical proof of concept, guided by strong scientific rationale and translational science.

Imugene’s SAB now includes some of the world's leading experts in cancer immunooncology therapy:

• SAB Chairman: Prof Dr Christoph Zielinski, Chairman, Comprehensive Cancer Centre in Vienna,

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

• Prof Dr Ursula Wiedermann, Chief Scientific Officer, co-inventor of HER-Vaxx, Professor of Vaccinology at the Medical University of Vienna.

• Dr Neil Segal, medical oncologist at Memorial Sloan Kettering Cancer Center New York

• Dr Yelena Janjigian, medical oncologist at the Memorial Sloan Kettering Cancer Center New York

• Prof Peter Schmid , Chair of Cancer Medicine at Barts Cancer Institute, Queen Mary University London

Leslie Chong, Imugene’s Chief Executive Officer welcomed Prof Schmid to the SAB and said: "We are honoured to have attracted another world leader in the field of cancer immuno-oncology to this respected group of experts. Their combined knowledge and experience will be invaluable as we rapidly progress our lead candidate through clinical development and support our goal to maximise the therapeutic potential for patients."

Imugene’s lead program is an anti-cancer vaccine called HER-Vaxx which seeks to improve on a combination of two widely proven therapies already in the market called Herceptin and Perjeta.

Imugene’s HER-Vaxx is designed to produce a response against a growth protein found on the cell surface in breast and gastric cancers.

Early studies have shown promise and a Phase Ib clinical trial is underway at eight hospitals across South-East Asia. The study seeks to test three different doses of HERVaxx in combination with chemotherapy and identify the optimal dose for a larger study.

For further information please contact:

Leslie Chong

Chief Executive Officer

E: Leslie.Chong@imugene.com

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

2

About Imugene (ASX:IMU)

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

3